Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biotechnology innovator developing intranasal immunotherapies for neurodegenerative and inflammatory diseases. This page provides centralized access to official corporate announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on TLSA's novel drug delivery platform, including progress with intranasal foralumab and other candidates targeting multiple sclerosis, Alzheimer's, and autoimmune conditions. The repository includes press releases on FDA communications, partnership announcements, and peer-reviewed research findings.
Key content categories include clinical trial milestones, intellectual property updates, executive leadership changes, and financial performance reports. All materials are sourced directly from the company and verified financial news outlets to ensure accuracy.
Bookmark this page for streamlined tracking of TLSA's progress in advancing non-invasive immunotherapy solutions. Check regularly for updates on groundbreaking approaches to modulating immune responses through nasal administration.
Tiziana Life Sciences (Nasdaq: TLSA) announced positive results from a six-month clinical trial of intranasal foralumab in a patient with Secondary Progressive Multiple Sclerosis (SPMS). The treatment was well-tolerated with no adverse reactions. Significant biological improvements included sustained inhibition of microglial activation and reduction of pro-inflammatory cytokines. The FDA authorized a second patient to receive therapy under an Expanded Access IND. A Key Opinion Leader (KOL) event will be held on March 14, 2022, to discuss findings.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its former subsidiary, AccuStem Sciences, published new data demonstrating that StemPrintER is a strong prognostic tool for distant recurrence risk in breast cancer. Analyzing 776 tumor samples from the TransATAC cohort showed that patients with a low StemPrintER Risk Score had a 5.8% risk of distant recurrence at 10 years, compared to 23.2% for high scores. This indicates StemPrintER's potential in clinical decision-making, alongside established tests.
Tiziana Life Sciences Ltd (Nasdaq: TLSA) has announced that CEO Dr. Kunwar Shailubhai will present at the 2022 BIO CEO & Investor Conference on February 14-15 in New York City. The company is pioneering novel immunotherapy delivery methods, focusing on its lead product, foralumab, an entirely human antibody. Recent studies suggest that nasally administered foralumab can effectively immunomodulate in COVID-19 patients and has shown promise for treating multiple sclerosis and inflammatory bowel diseases. Interim results will be shared in Q1 2022.
Tiziana Life Sciences Ltd (Nasdaq: TLSA) announced an amendment to its Investigational New Drug (IND) application for the oral formulation of foralumab, aimed at patients with mild-to-moderately active Crohn’s Disease. This would mark the first oral immunotherapy for this condition. If accepted by the FDA, Tiziana anticipates completing the Phase 1b clinical study by Q4 2022. The trial's primary focus is on safety, with a secondary assessment of pharmacodynamics. The amendment allows for a broader patient population and a shorter dosing regimen, addressing prior challenges in patient enrollment.
Tiziana Life Sciences Ltd (NASDAQ: TLSA) announced its CEO and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will participate in a virtual fireside chat at the B. Riley Securities 2022 Oncology Conference on January 27, 2022, at 4:00 p.m. EDT. The discussion will provide company updates focusing on breakthrough therapies for KRAS+ Non-Small Cell Lung Cancer and innovative drug delivery technologies. Tiziana's leading candidates include intranasal foralumab and milciclib, both showing favorable safety profiles and clinical responses in studies.
Tiziana Life Sciences (Nasdaq: TLSA) has announced a stock repurchase program authorized by its Board of Directors, allowing for the buyback of up to $5 million of the Company's common shares. This program is effective until December 31, 2022, and will utilize the Company's working capital. Executive Chairman Gabriele Cerrone expressed confidence in Tiziana’s growth opportunities, deeming the buyback an attractive use of capital, supported by a strong balance sheet. Tiziana develops innovative therapies through novel drug delivery methods that may enhance efficacy and safety.
Tiziana Life Sciences (Nasdaq: TLSA) announced the passing of Dr. Thomas Adams on January 9, 2022. He had served on the company's Board of Directors since February 2021. CEO Kunwar Shailubhai expressed deep sadness over Dr. Adams' loss, highlighting his value and inspiration to the team. Tiziana is focused on developing transformative therapies through innovative drug delivery methods, such as intranasal and oral routes, which aim to enhance safety and efficacy. The company’s lead candidates include intranasal foralumab and milciclib, showing promising safety profiles in clinical studies.
Tiziana Life Sciences (TLSA) announced a positive update regarding its treatment for secondary progressive multiple sclerosis (SPMS) using intranasal foralumab. The FDA has allowed enrollment of a second patient in the clinical trial, following favorable data from the first patient after three months of treatment, indicating safety and a positive response. Tiziana plans to expand its clinical trials in 2022 to address other conditions such as Crohn's Disease and Type 1 Diabetes. The ongoing monitoring of patient responses is expected to provide further insights by April 2022.
Tiziana Life Sciences (Nasdaq: TLSA) announced participation at the virtual Biotech Showcase Conference on January 10-12 and 17-19, 2022. Senior management will present and be available for one-on-one meetings throughout the event. Tiziana focuses on innovative drug delivery methods, including nasal, oral, and inhalation routes, to enhance immunotherapy efficacy and safety. Their lead candidates include intranasal foralumab and milciclib, both showing promising clinical results. For more details about the conference, registration is available online.
Tiziana Life Sciences plc has restructured its corporate framework by establishing Tiziana Life Sciences Ltd as its new parent company. This change, formalized on October 20, 2021, involved a two-for-one Share Capital Consolidation, allowing shareholders to maintain their ownership proportions. The newly consolidated shares commenced trading on NASDAQ on the same date. Tiziana continues its focus on developing innovative therapeutics for diseases including cancer, inflammation, and infections, notably progressing with its anti-CD3 monoclonal antibody, Foralumab.
FAQ
What is the current stock price of Tiziana Life Sciences Com (TLSA)?
What is the market cap of Tiziana Life Sciences Com (TLSA)?
